Cargando…
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Multiple myeloma (MM) is a plasma cell malignancy that is characterized by immune dysregulation. MM is commonly treated with immunomodulating agents, but still remains incurable. Herein, we proposed and evaluated immunostimulatory Lokon oncolytic adenoviruses (LOAd) for MM treatment. LOAd viruses ar...
Autores principales: | Wenthe, Jessica, Naseri, Sedigheh, Hellström, Ann-Charlotte, Wiklund, Helena Jernberg, Eriksson, Emma, Loskog, Angelica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725669/ https://www.ncbi.nlm.nih.gov/pubmed/32355275 http://dx.doi.org/10.1038/s41417-020-0176-9 |
Ejemplares similares
-
Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
por: Labani-Motlagh, Alireza, et al.
Publicado: (2021) -
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
por: Wenthe, Jessica, et al.
Publicado: (2021) -
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
por: Wenthe, Jessica, et al.
Publicado: (2023) -
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles
por: Loskog, Angelica
Publicado: (2015) -
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
por: Wenthe, Jessica, et al.
Publicado: (2022)